The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor compound, alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://lilyoend504688.angelinsblog.com/40560550/retatrutide-and-nicotinamide-adenine-dinucleotide-a-integrated-strategy-to-metabolic-health